Tristel (GB:TSTL) has released an update.
Tristel PLC announces the submission of a 510(k) Premarket Notification to the FDA for its unique high-level disinfectant, Tristel OPH, designed for ophthalmic devices. If cleared, it promises to revolutionize infection prevention in North American ophthalmic procedures, offering a fast and effective alternative to current low-level disinfectants. CEO Matt Sassone is optimistic about receiving FDA clearance by end of 2024 and is preparing for distribution agreements in the US.
For further insights into GB:TSTL stock, check out TipRanks’ Stock Analysis page.
